Your session is about to expire
← Back to Search
CAR T-Cell Therapy for Neuroblastoma and Osteosarcoma
Study Summary
This trial is testing a new cancer treatment that combines two existing ways of fighting disease: antibodies and T cells. Antibodies are molecules that fight infections and protect your body from diseases caused by bacteria and toxic substances. T cells are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected. The new treatment being researched is called autologous T lymphocyte chimeric antigen receptor cells (CAR) cells targeted against the disialoganglioside (GD2) antigen that express Interleukin (IL)-15, and the inducible caspase 9 safety switch (iC9
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can do most activities but may need help.My neuroblastoma has returned after completing initial intense treatment.My neuroblastoma worsened for the first time during initial intense treatment.I have another cancer that is growing and needs treatment.I do not have any known brain or spinal cord diseases.My initial diagnosis was confirmed as neuroblastoma or ganglioneuroblastoma.My brain functions are within normal ranges.I have high-risk neuroblastoma or osteosarcoma that's not responding to treatment.I do not need medication for seizures.You have had a bad reaction to cyclophosphamide or fludarabine in the past.My cancer's growth can be tracked with specific medical criteria.My neuroblastoma is high-risk and has not responded to treatment or has come back.My neuroblastoma hasn't fully responded after 4+ cycles of intense chemotherapy.You have had allergic reactions to products containing murine protein in the past.
Frequently Asked Questions
What is the participant count of this research endeavor?
"Affirmative. Clinicaltrials.gov's records affirm that this trial is still actively recruiting participants, having been initially uploaded on the 19th of February 2019 and most recently updated on 22nd September 2022. This research requires 18 people to fill two spots at different sites."
Could I be a candidate for this research trial?
"Currently, this clinical trial is seeking 18 participants between the ages of 18 months and 18 suffering from osteosarcoma. Eligibility requires that enrollees have a Lansky or Karnofsky performance score of 60 or above; possess written HIPAA authorization signed by legal guardian; life expectancy exceeding 12 weeks; histological confirmation of initial diagnosis for either neuroblastoma, ganglioneuroblastoma, first relapse post-multidrug frontline treatment, progressive disease during said therapy , persistent/refractory condition as defined by Revised INRC criteria after at least 4 cycles of induction chemo on an applicable high risk protocol (e"
What potential hazards are associated with iC9.GD2.CAR.IL-15 T-cells?
"Evidence of safety and efficacy regarding iC9.GD2.CAR.IL-15 T-cells is scant, thus our team at Power rated it a 1 on the scale from 1 to 3"
Are participants who are younger than 45 years of age accepted for this research trial?
"This experiment has a narrow age range of 18 Months to 18 years. There are 537 studies available for minors and 751 for seniors aged 65 or higher."
Does this study currently accept volunteers?
"Confirmatively, this clinical trial is still in search of participants. According to the repository on clinicaltrials.gov, its inception happened on February 19th 2019 and underwent a revision as recently as September 22nd 2022."
For what purposes is iC9.GD2.CAR.IL-15 T-cell treatment commonly prescribed?
"iC9.GD2.CAR.IL-15 T-cells are most frequently used for the treatment of multiple sclerosis, though they have also been applied to mixed-cell type lymphoma, leukemia, myelocytic acute and retinoblastoma cases with some success."
Has there been prior research done concerning iC9.GD2.CAR.IL-15 T-cells?
"The iC9.GD2.CAR.IL-15 T-cells have been studied since 1997 at City of Hope Comprehensive Cancer Center, resulting in 1275 finished studies to date and 889 still ongoing tests; many taking place in Chapel Hill, North carolina."
Share this study with friends
Copy Link
Messenger